DSpace Repository

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Show simple item record

dc.contributor.author Wheeler, D.C.
dc.contributor.author Stefansson, B.V.
dc.contributor.author Batiushin, M.
dc.contributor.author Bilchenko, O.
dc.contributor.author Cherney, D.Z.I.
dc.contributor.author Chertow, G.M.
dc.contributor.author Douthat, W.
dc.contributor.author Dwyer, J.P.
dc.contributor.author Escudero, E.
dc.contributor.author Pecoits-Filho, R.
dc.contributor.author Furuland, H.
dc.contributor.author Górriz, J.L.
dc.contributor.author Greene, T.
dc.contributor.author Haller, H.
dc.contributor.author Hou, F.F.
dc.contributor.author Kang, S.-W.
dc.contributor.author Isidto, R.
dc.contributor.author Khullar, D.
dc.contributor.author Mark, P.B.
dc.contributor.author McMurray, J.J.V.
dc.contributor.author Kashihara, N.
dc.contributor.author Nowicki, M.
dc.contributor.author Persson, F.
dc.contributor.author Correa-Rotter, R.
dc.contributor.author Rossing, P.
dc.contributor.author Toto, R.D.
dc.contributor.author Umanath, K.
dc.contributor.author Van Bui, P.
dc.contributor.author Wittmann, I.
dc.contributor.author Lindberg, M.
dc.contributor.author Sjöström, C.D.
dc.contributor.author Langkilde, A.M.
dc.contributor.author Heerspink, H.J.L.
dc.date.accessioned 2020-12-14T16:11:09Z
dc.date.available 2020-12-14T16:11:09Z
dc.date.issued 2020
dc.identifier.uri https://hdl.handle.net/20.500.12866/8855
dc.description.abstract BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. METHODS: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Mean eGFR was 43.1 mL/min/1.73 m2 and median UACR was 949 mg/g (108 mg/mmol). RESULTS: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1 mL/min/1.73 m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). CONCLUSIONS: Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D. © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Nephrology Dialysis Transplantation
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject chronic kidney disease en_US
dc.subject dapagliflozin en_US
dc.subject randomized controlled clinical trial en_US
dc.subject sodium–glucose co-transporter-2 inhibitor en_US
dc.title The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/ndt/gfaa234
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.20
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.13
dc.relation.issn 1460-2385


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics